rilzabrutinib expans continu preliminari outlook up
forma cash octob equiti rais
principia complet ipo sept
quarterli ep may add due increas share count
round posit ep base dilut share count
anticip data time pivot phase pegasu trial
pv vs prior guid principia continu progress
lead drug candid rilzabrutinib new gener name
pivot pegasu studi pemphigu vulgari pv recent
compani announc trial may experi faster-than-
anticip releas final result oppos mainli
due increas acceler enrol note on-going part
 phase trial pv demonstr posit clinic result
cr encourag major
patient receiv sub-optim therapeut dose drug mg
daili discuss may expect final result
phase part trial upcom medic confer
posit progress citp result
meet principia present posit clinic data itp
host kol event data updat kol comment
crucial takeaway presenc medic need
market potenti could signific novel
drug candid new clinic relev moa citp
rapid onset activ favor safeti profil suggest
potent safer btk inhibitor complet analysi trial
patient target go present upcom medic
confer
expans diseas rd initi phase
trial morn compani also announc
new initi potenti clinic commerci
expans highlight indic
target therapi thu far analyz patholog onset
indic note immune-medi disord
character chronic inflamm fibrosi target
cell autoantibodi product could clinic
relev might address mani aspect potenti
affect patholog featur diseas
inflamm allerg compon ige eosinophil monocyt
macrophag involv fibrosi cell prolifer given
high rate relaps current therapeut option includ rituxan
glucocorticoid satisfactori principia believ proven
effect safe monotherapi could becom attract
trial interestingli american colleg rheumatolog
rd diagnosi treatment guidelin might facilit futur clinic
develop new target approach
new guidelin led dr john stone md mph director clinic
rheumatolog massachusett gener hospit associ professor
medicin divis rheumatolog harvard medic school
definit distribut analyst rate analyst certif disclosur pleas refer page report
pv recap data expect on-going phase pegasu trial anticip
data releas project oppos pv show increas clinic activ part
phase studi vs part record patient reduc null diseas accord pdai score
mean cr addit increasingli look like better therapeut option approv soc
pv patient think least three crucial learn part higher clinic activ associ
increas chronic treatment occur time depend manner full analysi data
may help defin marker could predict respons find right dose may derisk overal trial detail
analysi part phase studi pv could found recent note referenc consist
messag day pv efficaci consid data observ investig on-going
pivot pegasu phase trial current enrol track pegasu trial random world-wide double-
blind placebo-control trial blind treatment period gaug efficaci safeti oral moder
sever pv patient vs placebo use background treatment taper dose corticosteroid cs approxim
patient newli diagnos relaps diseas enrol similar demograph phase studi primari
efficaci endpoint assess whether could drive durabl complet remiss low-dos cs mg/day
week treatment durabl complet remiss defin lesion heal addit lesion
appear least eight week secondari endpoint cumul cs use time complet remiss
week patient treat therapi open-label extens period week importantli
trial size phase similar two recent random control phase trial investig rituxan
arzerra pv data project
deep dive itp data releas principia releas posit initi data
phase trial address role r/r chronic itp citp patient treat primari
endpoint met gener popul high dose group respect data still
immatur howev highlight clinic rational evid progress r/r citp special focu
address hard treat itp patient belief although small number patient think result encourag
especi consid favor safeti profil demonstr thu far absenc anti-platelet aggreg
significantli differenti btk inhibitor ibrutinib potenti address hard
treat popul therapeut option includ tpo-ra refractori patient increas platelet count
achiev without need rescu medic increas activ associ higher dose per manag
complet analysi trial patient target go present upcom medic confer
discuss key data takeaway includ
confirm clinic activ regardless dose durat treatment patient achiev
primari endpoint consist consecut platelet count separ least five day platelet
count increas baselin without requir rescu medic addit patient record
two platelet count
higher respons rate associ higher dose bid optim dose demonstr
higher clinic activ patient treat higher drug dose mg mg twice daili follow least
week therapi high dose patient primari addit endpoint record patient
respect consid result mg bid dose could seen optim
earli sign respons associ achiev primari endpoint earli sign clinic respons
achiev platelet count record first week treatment patient met
primari endpoint higher start dose demonstr stabl sustain increas
platelet level could result therapeut dose rang lead higher target
engag howev given heterogen diseas exclud itp patient could
respons lower dose other convers higher dose may suitabl patient whose diseas
entail higher btk activ thu demand chronic higher dose schedul think clinic aspect could
easili address current trial use intra-pati dose escal featur
confirm safeti key differenti vs btk inhibitor show favor safeti profil across
dose treatment relat bleed thrombot event featur highli encourag compar
previous fail itp due safeti concern differenti moa revers coval btk
inhibitor relat treatment emerg advers event teae report patient grade
detail data could found recent note referenc itp data shine
long-term valu principia sharehold deriv program collabor sanofi
sni rate phase trial ms use brain tropic btk inhibitor principia option
co-fund phase trial follow phase data studi complet expect howev guidanc
data report confid program deriv promis pk/pd data hand
dose escal phase highlight abil reach brain tissu impact cell-driven inflamm local believ
highli differenti main peer merck rate evobrutinib valid btk target ms
evobrutinib pharma partnership valid note cross blood-brain barrier bbb potenti crucial
hit patholog inflammatori pathway microglia cell act brain macrophag lead better outcom
patient
valuat risk price target achiev reiter buy rate increas price target
base follow factor adjust base year increas project chanc success itp
adjust follow data increas project itp peak sale million
million ex-u market includ valuat increas project chanc success ms partner
sanofi san rate increas project peak sale billion million project
royalti principia current valuat base opportun pv follow increment
contribut itp ms bladder cancer pv project
launch base project chanc success billion million peak sale
respect itp model opportun project launch chanc success
million peak sale ms project launch chanc success billion peak
sale believ conserv lastli bladder cancer project launch
chanc success million peak sale current valu immunoproteasom program price target
base clinic net present valu npv model allow us flex multipl assumpt affect drug potenti
commerci profil factor could imped reach price target includ fail inconclus clinic trial inabl
compani secur adequ fund progress drug develop pathway
million except per share data
licens revenu
product royalti
provis tax
particip prefer stock
net incom common
number share basic
number share dilut
sec file wainwright estim
principia complet ipo septemb
licens revenu
product royalti
provis tax
particip prefer stock
net incom common
sec file wainwright estim
principia complet ipo septemb
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori principia biopharma inc prnb-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl januari
 wainwright co llc firm member finra sipc regist broker-deal
joseph pantgini ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur principia
biopharma inc includ without limit option right warrant futur long short posit
decemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic within
three month follow public research report
 wainwright co llc manag co-manag public offer secur inc
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
